Broad inhibition of Plasmodium falciparum cytoadherence by (+)-epigallocatechin gallate. by Patil, Pradeep R. et al.
This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted
PDF and full text (HTML) versions will be made available soon.
Broad inhibition of Plasmodium falciparum cytoadherence by
(+)-epigallocatechin gallate
Malaria Journal 2011, 10:348 doi:10.1186/1475-2875-10-348
Pradeep R Patil (patilpradeep@yahoo.co.in)
Sandra Gemma (gemma@unisi.it)
Giuseppe Campiani (campiani@unisi.it)
Alister G Craig (agcraig@liv.ac.uk)
ISSN 1475-2875
Article type Research
Submission date 12 September 2011
Acceptance date 1 December 2011
Publication date 1 December 2011
Article URL http://www.malariajournal.com/content/10/1/348
This peer-reviewed article was published immediately upon acceptance. It can be downloaded,
printed and distributed freely for any purposes (see copyright notice below).
Articles in Malaria Journal are listed in PubMed and archived at PubMed Central.
For information about publishing your research in Malaria Journal or any BioMed Central journal, go
to
http://www.malariajournal.com/authors/instructions/
For information about other BioMed Central publications go to
http://www.biomedcentral.com/
Malaria Journal
© 2011 Patil et al. ; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Broad inhibition of plasmodium falciparum 
cytoadherence by (+)-epigallocatechin gallate 
ArticleCategory : Research 
ArticleHistory : Received: 12-Sep-2011; Accepted: 24-Nov-2011 
ArticleCopyright : 
© 2011 Patil et al; licensee BioMed Central Ltd. This is an Open Access 
article distributed under the terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/2.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided 
the original work is properly cited. 
Pradeep R Patil,Aff1 Aff2 Aff3 
Email: patilpradeepr@yahoo.co.in 
Sandra Gemma,Aff1 
Email: gemma@unisi.it 
Giuseppe Campiani,Aff1 
Email: campiani@unisi.it 
Alister G Craig,Aff2 
Corresponding Affiliation: Aff1 
Email: agcraig@liv.ac.uk 
 
Aff1 European Research Centre for Drug Discovery and Development, 
Department of Pharmaceutical and Applied Chemistry,  University of 
Siena,  via Aldo Moro 2,  Siena  53100,  Italy 
Aff2 Liverpool School of Tropical Medicine,  Pembroke Place,  Liverpool  
L3 5QA,  UK 
Aff3 Université Montpellier II Sciences et Techniques,  Montpellier,  France 
Abstract 
Background 
The surface antigen PfEMP-1 is a key virulence factor of the human malaria parasite implicated 
in the cytoadherence of Plasmodium falciparum infected erythrocytes to a range of receptors on 
host endothelium. Among these host receptors, binding to ICAM-1 is related to cerebral malaria. 
The majority of the mortality in children with cerebral malaria is seen within 24 h of hospital 
admission despite the use of effective anti-parasite drugs, therefore, the development of 
adjunctive therapies is urgently needed. 
The polyphenolic compound (+)-epigallocatechin gallate ((+)-EGCG) has been previously 
evaluated for anti-adhesive properties using a small number of laboratory parasite isolates. Here, 
this property is further explored using a new panel of ICAM-1-binding patient isolates of P. 
falciparum to ascertain if (+)-EGCG might be effective as a broad spectrum inhibitor of ICAM-
1-based cytoadherence. 
Methods 
Plasmodium falciparum lines, including A4 and ItG as positive controls and nine new ICAM-1 
binding patient isolates, were allowed to bind with ICAM-1-Fc protein under static assay 
conditions in the presence and absence of 50 µM (+)-EGCG. Adhesion levels of all the parasite 
strains were quantified by microscopy as the mean number of infected erythrocyte (IE) bound 
per mm2 of surface area and statistical comparisons were made to demonstrate the effect of (+)-
EGCG on the binding of various parasite variants to human ICAM-1. 
Results 
This study revealed that binding of patient isolates to ICAM-1 was reduced significantly with 
inhibition levels of 37% in patient isolate BC-12 up to a maximum of 80% in patient isolate 8146 
at 50 µM (+)-EGCG. 
Conclusion 
Evaluation of the anti-adhesive property of (+)-EGCG against a new panel of ICAM-1-binding 
patient isolates of P. falciparum showed that this inhibitor, identified as potential mimic of the 
L43 loop of human ICAM-1, was effective at blocking cytoadherence. 
Keywords 
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Background 
Plasmodium falciparum malaria remains a major life-threatening parasitic disease, killing 
approximately 1 million people each year worldwide, mainly in sub-Saharan Africa [1]. Children 
and pregnant women are most susceptible. This infection can progress unpredictably to severe 
forms, including anaemia and cerebral malaria. The surface antigen PfEMP-1 (P. falciparum 
erythrocyte membrane protein-1) is a key virulence factor of the human malaria parasite, 
encoded by about 60 var genes per haploid genome [2]. PfEMP-1 variants have been implicated 
in the cytoadherence of P. falciparum-infected erythrocytes (IEs) to several binding receptors on 
host vascular endothelium [3-5], sequestering infected cells away from the spleen, which would 
otherwise destroy them. Switching of var gene expression allows the parasite to modify the 
antigenic and functional properties of IEs, thereby evading immunity and affecting infection 
outcome. In most cases the parasite expresses a single var gene at a time, maintaining all other 
members of the family in a transcriptionally silent state [6]. 
Among the many host receptors, binding to Intercellular Adhesion Molecule −1 (ICAM-1) has 
been shown to be related to cerebral malaria [7]. The majority of the mortality with cerebral 
malaria is seen within 24 h of hospital admission despite the use of effective anti-parasite drugs 
[8], therefore, the development of adjunctive therapies is urgently needed. The polyphenolic 
compound (+)-epigallocatechin gallate ((+)-EGCG) has been shown to have anti-adhesive 
properties [9]. This compound was identified using in silico molecular alignment techniques 
based on DE loop of human ICAM-1, which is a common feature of the ICAM-1 binding sites 
for at least the three P. falciparum laboratory variants tested [10]. (+)-EGCG inhibited binding of 
two variant ICAM-1 binding parasite lines at micromolar concentrations in a highly specific, 
dose-dependent manner. Interestingly, binding to CD36 was partially inhibited by EGCG in an 
ICAM-1-binding line, but not in a laboratory isolate that showed no binding to ICAM-1. In this 
current study the anti-adhesive properties of (+)-EGCG were measured against a new panel of 
ICAM-1-binding patient isolates of P. falciparum in order to evaluate the breadth of the 
cytoadherence inhibitory effect. 
Methods 
 
Recombinant protein and cytoadherence inhibitor 
(+)-EGCG, which is known to show anti-cytoadherence properties with A4 and ItG parasite 
strains, was used at 50 µM concentration. The purified receptor protein used in this study was 
human ICAM-1-Fc, which was prepared as previously described [11]. 
ICAM-1 selection of parasite lines using Dynabeads 
50 µl Protein A Dynabeads (Invitrogen) were washed 3 times with 500 µl PBS/1% BSA and then 
resuspended in 100 µl PBS/1%BSA. 2.5 µg ICAM-1-Fc protein was added to the bead 
suspension and made up to 400 µl by adding PBS/1%BSA. This was then incubated at room 
temperature by rotating for 1 h, again washed with 500 µl PBS/1% BSA using a magnet to retain 
the beads each time. Beads were resuspended in 200 µl PBS/1% BSA and stored at 4°C 
overnight. 
Parasite culture was enriched for trophozoite stages using Plasmion by standard protocols [12]. 
50 µl of Plasmion enriched parasites and 150 µl PBS/1% BSA were added to previously prepared 
ICAM-1 labelled Dynabeads. The mixture was incubated at room temperature, rotating for 45 
min then gently washed twice with 500 µl PBS/1% BSA using a magnet to retain the beads each 
time. Beads were resuspended in parasite media and cultured with fresh washed red blood cells 
(RBCs). 
Parasite culture 
Plasmodium falciparum lines used in this study were the laboratory lines A4 and ItG, as a 
positive controls, and patient isolates PO-69, PCM-7, GL-6, BC-31, BC-12, 8206, 8146, 8131, 
6392, which have previously been selected for binding to ICAM-1. Separate experiments had 
shown, using mutant ICAM-1 proteins, that all the ICAM-1-binding isolates used in this study 
have the L43 loop of ICAM-1 as a critical part of their binding site. To minimize the effect of 
antigenic switching in vitro the selected parasite lines were maintained in culture for not more 
than 3 weeks post-selection. RBCs for parasite culture were purified away from mononuclear 
cells and granulocytes using Lymphoprep. 
Parasites were grown to maturity for 24–48 h from frozen stabilates. Laboratory parasite lines 
and parasites from patient isolates were cultured at 1% haematocrit in group O human 
erythrocytes using standard culturing techniques, using RPMI 1640 medium (supplemented with 
37.5 mM HEPES, 7 mM D-glucose, 6 mM NaOH, 40 µg gentamicin sulfate/ml, 2 mM L-
glutamine, and 10% human serum) at a pH of 7.2 in a gas mixture of 96% nitrogen, 3% carbon 
dioxide, and 1% oxygen. The parasitaemia was calculated by determination of the number of IEs 
per 500 red blood cells (RBC) for thin blood films. Baseline RBC counts were used to calculate 
the parasite density (parasites/µl). For all adhesion assays the IE suspension was adjusted to 3% 
parasitaemia and 1% haematocrit. 
Static adhesion assays 
Purified recombinant ICAM-1-Fc protein and PBS only (as negative control) were spotted in 
triplicate in a radial pattern using 2 µl spots on 60 x 50 mm bacteriological plastic Petri dishes 
(Falcon 1007; Becton Dickinson, Oxford, UK) at concentrations of 50 µg/ml for ICAM-1. This 
concentration had previously been shown to be within the dynamic range for detecting 
differences in adhesion and produce coated surfaces with receptors at levels approximately equal 
to receptor densities seen on activated endothelium [13]. The dishes were placed in a humidified 
chamber for 2 h at 37°C to allow the proteins to adsorb to the surface of Petri dish, after which 
the protein solution and PBS were aspirated off and the uncoated plastic area was blocked 
overnight with 1% BSA/PBS at 4°C. The plates were warmed at 37°C for one hour, blocking 
solution (1% BSA/PBS) was removed and plates were washed with binding buffer (RPMI 1640 
with 0.2% glucose) prior to adding 1.5 ml of parasite culture (3% parasitaemia; 1% haematocrit 
in binding medium), with and without 50 µM (+)-EGCG. The plates were incubated at 37°C for 
one hour with gentle resuspension every 10 min. Unbound infected and uninfected erythrocytes 
were removed by gentle manual washing (4–6 washes) with 2 ml binding medium per wash 
(monitoring of adhered cells was performed using an inverted microscope). The adhered IEs 
were fixed with 1% glutaraldehyde in phosphate buffered saline for 1 h and stained with 10% 
Giemsa for 30 min. Adhesion levels of all parasite strains (with and without (+)-EGCG) were 
quantified by microscopy using a unique, anonymous identifier for each dish (with the operator 
blinded to the IE category) and results were expressed as the mean number of IEs bound per 
mm2 of surface area. Inhibition experiments were conducted twice for isolates PO-69, 8206 and 
8131, and three times for the other parasite lines. The results were compared to quantify the 
effect of (+)-EGCG on binding of various ICAM-1-binding patient isolates to human ICAM-1. 
Results and discussion 
This study focussed on the ability of the naturally occurring polyphenolic compound (+)-EGCG 
to inhibit the binding of various patient isolates to ICAM-1. All the isolates tested showed 
significantly reduced adhesion with inhibition ranging from 37%–80% (Figure 1). This varying 
degree of inhibition of various patient isolates by (+)-EGCG, may refer to variable contact 
residues on PfEMP-1 of different patient isolates involved in the binding with ICAM-1 as seen in 
previous studies [10]. 
Figure 1  Screening of (+)-EGCG against new ICAM-1 binding patient isolates of P. 
falciparum. EGCG was used at 50 µM concentration during the binding assays. Results are 
shown as mean inhibition (compared to no inhibitor control) ± standard deviation 
On the basis of these results it can be concluded that, despite the variation in the contact residues 
engaged on the BED side of ICAM-1 by different PfEMP-1 variants [14], some structural 
similarity is retained. It seems likely that the L-43 loop of human ICAM-1 is a key domain in the 
interaction with PfEMP-1 based on the observation that the whole set of ICAM-1 binding patient 
isolates was inhibited by (+)-EGCG, which is known to mimic L-43 loop of ICAM-1. Although 
several other binding activities use the N-terminal domain of ICAM-1 (e.g. T-cells, rhinovirus, 
fibrinogen), the L43 loop appears to be unique to P. falciparum-infected erythrocytes, supporting 
its use as a starting point for the design of specific inhibitors of cytoadherence. However, there 
are still a number of issues that still need to be resolved before taking (+)-EGCG further, such as 
its ability to reverse existing cytoadherence rather than just inhibition of new binding and testing 
the compound for disruption of ICAM-1-dependent IE binding in the context of endothelial cells. 
Also, to improve the pharmacological characteristics of (+)-EGCG, it is necessary to ‘remake’ 
the chemical scaffold to produce a lead structure that is more amenable to chemical synthesis. 
These experiments are underway. 
Conclusions 
(+)-EGCG is able to inhibit binding to ICAM-1 by a range of patient-derived parasite isolates. 
This supports further development of anti-adhesive compounds with broad reactivity based on 
this chemical scaffold as novel adjunct therapies for cerebral malaria. 
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